Free Functional Assessment
AI-powered root cause analysis & care plan
Start Free
Preferred vendor Β· Learn more
The Ipamorelin + CJC-1295 + Tesamorelin triple stack is the most comprehensive growth hormone secretagogue protocol available. Ipamorelin is a selective GHSR agonist that triggers pulsatile GH release without cortisol or prolactin elevation. CJC-1295 DAC extends GHRH signaling with a half-life of 6-8 days, amplifying overall GH output. Tesamorelin is an FDA-approved GHRH analog specifically targeting visceral adipose tissue. Together, these three peptides synergize at different points: CJC-1295 provides sustained GHRH baseline, ipamorelin triggers acute GH pulses, and tesamorelin adds GHRH signaling with preferential visceral fat reduction.
This stack targets three points on the GH axis simultaneously. CJC-1295 DAC provides a sustained GHRH baseline that elevates tonic GH secretion. Ipamorelin triggers acute GH pulses via ghrelin receptor agonism, creating the pulsatile pattern essential for fat loss and tissue repair. Tesamorelin adds additional GHRH signaling with unique visceral fat targeting proven in clinical trials.
The triple approach creates a more physiologic GH profile than any dual combination. CJC-1295 elevates the baseline, ipamorelin creates peaks, and tesamorelin specifically addresses visceral adiposity. Clinical data on tesamorelin (Egrifta) shows it reduces visceral fat by 15-20% independently, and this effect compounds with the other two secretagogues.
| Protocol | Compound 1 | Compound 2 | Timing | Duration |
|---|---|---|---|---|
| Standard | Ipa 200mcg 2x/day + CJC 2mg/wk | Tesa 2mg/day | AM/PM Ipa, weekly CJC, AM Tesa | 12 weeks |
| Advanced | Ipa 300mcg 3x/day + CJC 2mg/wk | Tesa 2mg/day | AM/pre-workout/PM | 16 weeks |
| Pulse | Ipa 200mcg 2x/day (5on/2off) + CJC 2mg/wk | Tesa 2mg daily | Weekdays Ipa | 12 weeks |
| Panel | Markers | Timing |
|---|---|---|
| GH/IGF-1 | IGF-1, GH (fasted morning) | Baseline, Week 6, Week 12 |
| Metabolic | Fasting glucose, insulin, HbA1c | Baseline, Week 8 |
| Lipid | Cholesterol panel | Baseline, Week 12 |
| Basic | CBC, CMP | Baseline, Week 8 |
IGF-1 is the key marker. Target range: 200-350 ng/mL. Values above 350 warrant dose reduction. Monitor fasting glucose.
When properly dosed and monitored via IGF-1 blood work, it has a good safety profile. Keep IGF-1 at 200-350 ng/mL. Cycling (12 weeks on, 4 off) prevents desensitization.
Tesamorelin and ipamorelin fasted AM (30 min apart), ipamorelin again before bed. CJC-1295 DAC once weekly. All fasted, since carbs and fats blunt GH release.
It targets three distinct GH axis points. CJC-1295 DAC provides sustained GHRH baseline, ipamorelin triggers acute GH pulses via ghrelin receptor, and tesamorelin adds GHRH stimulation with unique visceral fat targeting. This multi-point approach produces higher, more physiologic GH output.
When properly dosed and monitored via IGF-1 blood work, it has a good safety profile. Keep IGF-1 at 200-350 ng/mL. Cycling (12 weeks on, 4 off) prevents desensitization.
Tesamorelin and ipamorelin fasted AM (30 min apart), ipamorelin again before bed. CJC-1295 DAC once weekly. All fasted, since carbs and fats blunt GH release.
It targets three distinct GH axis points. CJC-1295 DAC provides sustained GHRH baseline, ipamorelin triggers acute GH pulses via ghrelin receptor, and tesamorelin adds GHRH stimulation with unique visceral fat targeting. This multi-point approach produces higher, more physiologic GH output.
When properly dosed and monitored via IGF-1 blood work, it has a good safety profile. Keep IGF-1 at 200-350 ng/mL. Cycling (12 weeks on, 4 off) prevents desensitization.
Tesamorelin and ipamorelin fasted AM (30 min apart), ipamorelin again before bed. CJC-1295 DAC once weekly. All fasted, since carbs and fats blunt GH release.